CalciMedica, Inc. Common Stock

Day range

$1.25 – $1.50

Open

$1.26

Prev close

$1.23

Volume

151.57K

Market cap

$8.4M

Shares out

6.83M

P/E

—

P/S

—

P/B

1.52

P/FCF

—

ROE

-385.3%

ROA

-108.9%

Debt/Equity

1.67

Div yield

0.00%

As of Oct 23, 2026

• Cfo departureOct 16, 2026

  On October 15, 2026, Stephen Bardin, the Chief Financial Officer, principal accounting officer and principal financial officer of CalciMedica, Inc. (the "Company"), provided notice of his resignation, to be effective immediately following the filing of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to pursue another professional opportunity. Mr. Bardin's resignation was not due to any disagreement with the Company.

• Underwriting agreementSep 30, 2026

  The Company may offer and sell Common Stock having an aggregate offering price of up to $25,000,000 from time to time under the Company's at-the-market offering agreement (the "Offering Agreement") with H.C. Wainwright & Co., dated August 11, 2023.

• Listing compliance regainedSep 16, 2026

  On September 15, 2026, the Company received a letter from the Staff notifying the Company that the Staff has determined that for 10 consecutive business days, from August 31, 2026 to September 14, 2026, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2).

• Stock splitSep 2, 2026

  As previously disclosed, at 5:00 p.m. (Eastern Time) on August 28, 2026, the Company implemented a one-for-five reverse stock split of its outstanding common stock.

• Charter amendmentAug 27, 2026

  CalciMedica, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reduction in the total number of authorized shares of its common stock from 500,000,000 to 100,000,000.

Days to cover

1.5

Short interest

86.43K

Avg volume

57.73K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Hypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
  positiveGlobeNewswire Inc.· Sep 16, 2026
• Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
  Zacks Investment Research· May 23, 2024
• CalciMedica And 2 Other Penny Stocks Insiders Are Buying
  Benzinga· Apr 3, 2024
• Top 4 Health Care Stocks That May Crash This Quarter
  Benzinga· Feb 2, 2024
• Gannett And 3 Other Stocks Under $4 Insiders Are Buying
  Benzinga· Nov 7, 2023